KD Logo

Cullinan Therapeutics Inc (CGEM) may enjoy gains as insiders got busy in the recent days

Cullinan Therapeutics Inc’s recent filing unveils that its Chief Scientific Officer Michaelson Jennifer unloaded Company’s shares for reported $0.13 million on Jul 05 ’24. In the deal valued at $16.33 per share,8,000 shares were sold. As a result of this transaction, Michaelson Jennifer now holds 123,942 shares worth roughly $2.0 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Then, Michaelson Jennifer sold 5,606 shares, generating $168,516 in total proceeds. Upon selling the shares at $30.06, the Chief Scientific Officer now owns 129,582 shares.

Before that, Michaelson Jennifer sold 58,000 shares. Cullinan Therapeutics Inc shares valued at $1,628,159 were divested by the Chief Scientific Officer at a price of $28.07 per share. As a result of the transaction, Michaelson Jennifer now holds 129,582 shares, worth roughly $2.09 million.

Stifel initiated its Cullinan Therapeutics Inc [CGEM] rating to a Buy in a research note published on May 01, 2024; the price target was $40. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in mid April with a ‘”an Outperform”‘ rating. Wedbush began covering CGEM with “an Outperform” recommendation on February 15, 2024. TD Cowen started covering the stock on June 15, 2023. It rated CGEM as “an Outperform”.

Price Performance Review of CGEM

On Tuesday, Cullinan Therapeutics Inc [NASDAQ:CGEM] saw its stock fall -1.65% to $16.14. Over the last five days, the stock has lost -3.53%. Cullinan Therapeutics Inc shares have risen nearly 58.39% since the year began. Nevertheless, the stocks have risen 57.00% over the past one year. While a 52-week high of $30.19 was reached on 05/07/24, a 52-week low of $7.64 was recorded on 01/11/24. SMA at 50 days reached $22.27, while 200 days put it at $15.04. A total of 0.34 million shares were traded, compared to the trading of 0.46 million shares in the previous session.

Levels Of Support And Resistance For CGEM Stock

The 24-hour chart illustrates a support level at 15.90, which if violated will result in even more drops to 15.65. On the upside, there is a resistance level at 16.42. A further resistance level may holdings at 16.69. The Relative Strength Index (RSI) on the 14-day chart is 33.20, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.55, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.99%. Stochastics%K at 16.72% indicates the stock is a buying.

The most recent change occurred on November 21, 2022 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $20 price target.

Most Popular